Supernus Pharmaceuticals Inc

S49

Company Profile

  • Business description

    Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

  • Contact

    9715 Key West Avenue
    RockvilleMD20850
    USA

    T: +1 301 838-2500

    E: [email protected]

    https://www.supernus.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    674

Stocks News & Analysis

stocks

Earnings from our top global lithium pick

Shares rise on improved free cash flow generation.
stocks

After slump this ASX share may be an opportunity

Lower than expected guidance led to a sell-off.
stocks

Investment decisions in overvalued bank drive strong results

Shares fall despite a broadly unchanged outlook.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,109.4052.500.58%
CAC 408,055.51105.331.32%
DAX 4023,959.99390.031.65%
Dow JONES (US)47,353.85366.750.78%
FTSE 1009,787.15104.581.08%
HKSE26,649.06407.231.55%
NASDAQ23,524.25519.712.26%
Nikkei 22550,911.76635.391.26%
NZX 50 Index13,617.4818.270.13%
S&P 5006,829.74100.941.50%
S&P/ASX 2008,835.9044.100.50%
SSE Composite Index4,018.6021.040.53%

Market Movers